title: [Hemolytic anemia under erlotinib treatment].
abstract: Erlotinib is a tyrosine kinase inhibitor widely prescribed of which the most common sides effects are grade I or II rash and diarrhea. We report two cases of hemolytic anemia (HA) induced by erlotinib. Our two patients were treated with erlotinib after a prior line of systemic platinum-doublet therapy for metastatic non-small cell lung cancer. Both patients presented, shortly after starting treatment with erlotinib, an HA which was fatal for one of them. To our knowledge, this major side effect of erlotinib has not been reported in the literature. We will try through this article to make a literature review of the most important side effects of erlotinib and we will also focus on the HA induced by other molecules used in oncology.
authors.affiliation: Service de pneumologie, pôle de cancérologie, médecine aiguë et communautaire, CHU Michallon, boulevard de la Chantourne, BP 217, 38043 Grenoble cedex 9, France. Electronic address: lsakhri@chu-grenoble.fr.
authors.forename: L
authors.initials: L
authors.lastname: Sakhri
authors.affiliation: Service de pneumologie, nouvel hôpital civil, 1, place de l'Hôpital, BP 426, 67091 Strasbourg cedex, France.
authors.forename: B
authors.initials: B
authors.lastname: Mennecier
authors.affiliation: Service de pneumologie, nouvel hôpital civil, 1, place de l'Hôpital, BP 426, 67091 Strasbourg cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Quoix
mesh_terms: D000369:Aged, 80 and over; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride
keywords: Anémie hémolytique; Cancer bronchique; Effets secondaires; Erlotinib; Hemolytic anemia; Lung cancer; Side effects